Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Strong Trading Volume – Here’s Why

Zealand Pharma A/S (OTCMKTS:ZLDPF) saw unusually-strong trading volume on Thursday . 2,055 shares were traded during mid-day trading, a decline of 34% from the previous session’s volume of 3,096 shares.The stock last traded at $45.0150 and had previously closed at $45.50.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Berenberg Bank downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, June 17th. Wolfe Research lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, June 11th. Finally, Jefferies Financial Group cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Zealand Pharma A/S currently has a consensus rating of “Hold”.

Zealand Pharma A/S Price Performance

The company has a fifty day moving average of $45.84 and a 200-day moving average of $51.28. The company has a current ratio of 37.17, a quick ratio of 37.17 and a debt-to-equity ratio of 0.02. The stock has a market cap of $3.22 billion, a PE ratio of 3.34 and a beta of 0.88.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last announced its earnings results on Thursday, May 7th. The company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.50. The company had revenue of $5.33 million during the quarter, compared to analysts’ expectations of $2.81 million. Zealand Pharma A/S had a return on equity of 41.80% and a net margin of 68.82%. Sell-side analysts expect that Zealand Pharma A/S will post 2.37 EPS for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.